TY  - JOUR
AU  - Paz-Ares, Luis
AU  - Luft, Alexander
AU  - Vicente, David
AU  - Tafreshi, Ali
AU  - Gümüş, Mahmut
AU  - Mazières, Julien
AU  - Hermes, Barbara
AU  - Çay Şenler, Filiz
AU  - Csőszi, Tibor
AU  - Fülöp, Andrea
AU  - Rodríguez-Cid, Jerónimo
AU  - Wilson, Jonathan
AU  - Sugawara, Shunichi
AU  - Kato, Terufumi
AU  - Lee, Ki Hyeong
AU  - Cheng, Ying
AU  - Novello, Silvia
AU  - Halmos, Balazs
AU  - Li, Xiaodong
AU  - Lubiniecki, Gregory M
AU  - Piperdi, Bilal
AU  - Kowalski, Dariusz M
AU  - KEYNOTE-407 Investigators
PY  - 2018
DO  - 10.1056/NEJMoa1810865
UR  - http://hdl.handle.net/10668/13017
T2  - The New England journal of medicine
AB  - Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently,...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carboplatin
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Intention to Treat Analysis
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Paclitaxel
KW  - Programmed Cell Death 1 Receptor
KW  - Progression-Free Survival
KW  - Survival Analysis
TI  - Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
TY  - research article
VL  - 379
ER  -